The Gilbert Family Foundation (GFF) announced the launch of a clinical study that aims to validate optical coherence tomography (OCT) as a tool to objectively assess the visual system and its response to treatment in NF1 patients with optic pathway gliomas.

The Gilbert Family Foundation (GFF) is excited to announce the development of a database for neurofibromatosis type 1 (NF1) research tools in collaboration with Sage Bionetworks. The database aims to support the development of a robust NF1 research toolkit while also lowering the barrier of entry to research for new-to-NF1 investigators. GFF and Sage intend the database to be used by a variety of stakeholders in the NF1 research community, including researchers, drug developers, and research funders.

DETROIT, March 25, 2021 – The Gilbert Family Foundation (GFF) and Rocket Community Fund today announced an unprecedented and transformational $500 million philanthropic investment over the next ten years, to be accomplished through strategic contributions to community organizations that will build economic opportunity in Detroit neighborhoods. The Gilbert Family Foundation will contribute $350 million, and […]

On April 10, 2020, the FDA approved the first drug that was ever developed for neurofibromatosis type 1 (NF1). Selumetinib (aka AstraZeneca’s Koselugo) has been approved to treat symptomatic and inoperative NF1-associated plexiform neurofibromas and is currently in the midst of clinical trials to evaluate the possible benefits to other NF1-associated tumors.